NCT03960606 is a Phase 2 clinical trial of PUR1900 in Allergic Bronchopulmonary Aspergillosis, sponsored by Pulmatrix Inc..

Who is sponsoring NCT03960606?

NCT03960606 is sponsored by Pulmatrix Inc..

What drugs are being tested in NCT03960606?

Interventions in NCT03960606: PUR1900, Placebo.

What condition does NCT03960606 study?

NCT03960606 studies Allergic Bronchopulmonary Aspergillosis.

Is NCT03960606 still recruiting?

NCT03960606 is currently terminated. Last updated 27 August 2021.

Last reviewed 2021-08-27 · How we verify

NCT03960606

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Terminated Phase 2 Last updated 27 August 2021

What this trial tests

Phase 2 trial testing PUR1900 in Allergic Bronchopulmonary Aspergillosis in 7 participants. Terminated before completion.

Timeline

31 July 2019

Primary endpoint
14 July 2020

14 July 2020

Quick facts

Lead sponsor	Pulmatrix Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	7
Start date	31 July 2019
Primary completion	14 July 2020
Estimated completion	14 July 2020
Sites	20 locations across United Kingdom, Poland, Australia, United States, India

Drugs / interventions tested

PUR1900
Placebo

Conditions studied

Allergic Bronchopulmonary Aspergillosis — all drugs for Allergic Bronchopulmonary Aspergillosis →

Sponsor

Pulmatrix Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Allergic Bronchopulmonary Aspergillosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Allergic Diseases Caused by <i>Aspergillus</i> Species in Patients with Cystic Fibrosis.
Curran AK, Hava DL. · · 2021 · cited 5× · PMID 33800658 · DOI 10.3390/antibiotics10040357
Future Directions for Clinical Respiratory Fungal Research.
Armstrong-James D. · · 2021 · cited 3× · PMID 34590208 · DOI 10.1007/s11046-021-00579-5

Verify or expand the search:

Other recruiting trials for Allergic Bronchopulmonary Aspergillosis

Currently open trials in the same condition.

NCT07362667 — A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA · recruiting
NCT07530770 — Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis · recruiting
NCT06244979 — iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine · Phase 2 · recruiting
NCT07362693 — A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA · recruiting
NCT05444946 — Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome · NA · recruiting

Other Pulmatrix Inc. trials

Trials by the same sponsor.

NCT05667662 — Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA · Phase 2 · terminated
NCT05351086 — A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults · Phase 1 · completed
NCT04759807 — A Phase 1b Study of PUR1800 in Patients With COPD · Phase 1 · completed
NCT03479411 — Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03960606 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pulmatrix Inc.
Last refreshed: 27 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03960606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing